Cargando…
Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation
Proprotein convertase subtilisin/kexin type-9 (PCSK9) is a secreted protein that binds to the epidermal growth factor-like-A domain of the low density lipoprotein receptor (LDLR) and mediates LDLR degradation in liver. Gain-of-function mutations in PCSK9 are associated with autosomal dominant hyperc...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Biochemistry and Molecular Biology
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3605646/ https://www.ncbi.nlm.nih.gov/pubmed/23400816 http://dx.doi.org/10.1074/jbc.M112.421370 |
_version_ | 1782263925715238912 |
---|---|
author | Kosenko, Tanja Golder, Mia Leblond, Geoffrey Weng, Willy Lagace, Thomas A. |
author_facet | Kosenko, Tanja Golder, Mia Leblond, Geoffrey Weng, Willy Lagace, Thomas A. |
author_sort | Kosenko, Tanja |
collection | PubMed |
description | Proprotein convertase subtilisin/kexin type-9 (PCSK9) is a secreted protein that binds to the epidermal growth factor-like-A domain of the low density lipoprotein receptor (LDLR) and mediates LDLR degradation in liver. Gain-of-function mutations in PCSK9 are associated with autosomal dominant hypercholesterolemia in humans. Size-exclusion chromatography of human plasma has shown PCSK9 to be partly associated with undefined high molecular weight complexes within the LDL size range. We used density gradient centrifugation to isolate LDL in plasma pooled from 5 normolipidemic subjects and report that >40% of total PCSK9 was associated with LDL. Binding of fluorophore-labeled recombinant PCSK9 to isolated LDL in vitro was saturable with a K(D) ∼ 325 nm. This interaction was competed >95% by excess unlabeled PCSK9, and competition binding curves were consistent with a one-site binding model. An N-terminal region of the PCSK9 prodomain (amino acids 31–52) was required for binding to LDL in vitro. LDL dose-dependently inhibited binding and degradation of cell surface LDLRs by exogenous PCSK9 in HuH7 cells. LDL also inhibited PCSK9 binding to mutant LDLRs defective at binding LDL. These data suggest that association of PCSK9 with LDL particles in plasma lowers the ability of PCSK9 to bind to cell surface LDLRs, thereby blunting PCSK9-mediated LDLR degradation. |
format | Online Article Text |
id | pubmed-3605646 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | American Society for Biochemistry and Molecular Biology |
record_format | MEDLINE/PubMed |
spelling | pubmed-36056462013-03-22 Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation Kosenko, Tanja Golder, Mia Leblond, Geoffrey Weng, Willy Lagace, Thomas A. J Biol Chem Lipids Proprotein convertase subtilisin/kexin type-9 (PCSK9) is a secreted protein that binds to the epidermal growth factor-like-A domain of the low density lipoprotein receptor (LDLR) and mediates LDLR degradation in liver. Gain-of-function mutations in PCSK9 are associated with autosomal dominant hypercholesterolemia in humans. Size-exclusion chromatography of human plasma has shown PCSK9 to be partly associated with undefined high molecular weight complexes within the LDL size range. We used density gradient centrifugation to isolate LDL in plasma pooled from 5 normolipidemic subjects and report that >40% of total PCSK9 was associated with LDL. Binding of fluorophore-labeled recombinant PCSK9 to isolated LDL in vitro was saturable with a K(D) ∼ 325 nm. This interaction was competed >95% by excess unlabeled PCSK9, and competition binding curves were consistent with a one-site binding model. An N-terminal region of the PCSK9 prodomain (amino acids 31–52) was required for binding to LDL in vitro. LDL dose-dependently inhibited binding and degradation of cell surface LDLRs by exogenous PCSK9 in HuH7 cells. LDL also inhibited PCSK9 binding to mutant LDLRs defective at binding LDL. These data suggest that association of PCSK9 with LDL particles in plasma lowers the ability of PCSK9 to bind to cell surface LDLRs, thereby blunting PCSK9-mediated LDLR degradation. American Society for Biochemistry and Molecular Biology 2013-03-22 2013-02-11 /pmc/articles/PMC3605646/ /pubmed/23400816 http://dx.doi.org/10.1074/jbc.M112.421370 Text en © 2013 by The American Society for Biochemistry and Molecular Biology, Inc. Author's Choice—Final version full access. Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) applies to Author Choice Articles |
spellingShingle | Lipids Kosenko, Tanja Golder, Mia Leblond, Geoffrey Weng, Willy Lagace, Thomas A. Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation |
title | Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation |
title_full | Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation |
title_fullStr | Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation |
title_full_unstemmed | Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation |
title_short | Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation |
title_sort | low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (pcsk9) in human plasma and inhibits pcsk9-mediated low density lipoprotein receptor degradation |
topic | Lipids |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3605646/ https://www.ncbi.nlm.nih.gov/pubmed/23400816 http://dx.doi.org/10.1074/jbc.M112.421370 |
work_keys_str_mv | AT kosenkotanja lowdensitylipoproteinbindstoproproteinconvertasesubtilisinkexintype9pcsk9inhumanplasmaandinhibitspcsk9mediatedlowdensitylipoproteinreceptordegradation AT goldermia lowdensitylipoproteinbindstoproproteinconvertasesubtilisinkexintype9pcsk9inhumanplasmaandinhibitspcsk9mediatedlowdensitylipoproteinreceptordegradation AT leblondgeoffrey lowdensitylipoproteinbindstoproproteinconvertasesubtilisinkexintype9pcsk9inhumanplasmaandinhibitspcsk9mediatedlowdensitylipoproteinreceptordegradation AT wengwilly lowdensitylipoproteinbindstoproproteinconvertasesubtilisinkexintype9pcsk9inhumanplasmaandinhibitspcsk9mediatedlowdensitylipoproteinreceptordegradation AT lagacethomasa lowdensitylipoproteinbindstoproproteinconvertasesubtilisinkexintype9pcsk9inhumanplasmaandinhibitspcsk9mediatedlowdensitylipoproteinreceptordegradation |